secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harpoon Therapeutics, Inc. (—)
CIK:        0001708493
Form:       8-K
Filed at:   2024-03-11T23:59:59+00:00
Accession:  0001193125-24-064395
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Merck completes acquisition of Harpoon Therapeutics for $23.00 per share in cash
--------------------------------------------------------------------------------

- Merck acquired Harpoon for $23.00 per common share in cash, closing on March 11, 2024.
- Each preferred share entitled to $3,577.77; outstanding stock options and RSUs cashed out.
- Harpoon Common Stock to be delisted from Nasdaq; reporting obligations will be suspended.
- Board of directors (incl. Joseph Bailes, Mark Chin, etc.) resigned at effective time.
- Sales agreement with Cantor Fitzgerald terminated upon closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708493/000119312524064395/0001193125-24-064395-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708493/000119312524064395/d808382d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-064395

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer